Skip to main content

Table 3 Patient immune profiles correlating with clinical frailty in the whole population (the CTG and CG) prior to receiving systemic therapy at baseline

From: Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty

Geriatric measure Phenotype p Value, r value, number
LOFS CD4+/CD57+ 0.0178, r = 0.341, n = 48
LOFS CD8+/CD27 0.0367, r = 0.302, n = 48
LOFS CD4+/CD25hi FOXP3+ 0.0407, r = 0.291, n = 50
LOFS CD4+/FOXP3+ 0.0002, r = 0.510, n = 50
LOFS CD14-negative/CD15+/CD124+ 0.0292, r = 0.303, n = 52
LOFS CD14-negative/HLA-DR-negative/CD11b+ 0.0195, r = 0.323, n = 52
LOFS CD15+ 0.0246, r = -0.311, n = 52
G8 CD4+/FOXP3+ 0.0147, r = 0.340, n = 51
G8 CD14-ve/HLA-DR-negative/CD11b+ 0.0403, r = 0.280, n = 54
  1. Negative r values indicate inverse association and positive r values show positive correlation between patient geriatric status (“Geriatric measure”) and the indicated leukocyte population (“Phenotype”). Lower G8 and Leuven oncology frailty score (LOFS) values designate more frail patients and high values indicate fitter patients. CTG chemotherapy group, CG control group